Comparison of Dopamine and Norepinephrine in the Treatment of Shock (SOAP-II)
Source: View publication →
The SOAP-II trial demonstrated no significant difference in 28-day mortality between dopamine and norepinephrine as first-line vasopressor therapy for shock, although dopamine was associated with a higher incidence of cardiac arrhythmias.
Key Findings
Study Design
Study Limitations
Clinical Significance
The SOAP-II trial effectively shifted clinical practice away from using dopamine as a first-line vasopressor in most shock states, favoring norepinephrine due to its superior safety profile regarding arrhythmic complications and efficacy as a vasopressor.
Historical Context
Prior to SOAP-II, both dopamine and norepinephrine were considered acceptable first-line vasopressors in clinical guidelines. This landmark trial provided rigorous evidence to challenge the routine use of dopamine, particularly in patients at high risk for arrhythmias or with cardiogenic shock, and fundamentally altered global resuscitation protocols.
Guided Discussion
High-yield insights from every perspective
Based on the receptor profiles of dopamine and norepinephrine, what is the physiological basis for the higher incidence of tachyarrhythmias observed in the dopamine group of the SOAP-II trial?
Key Response
Dopamine has potent, dose-dependent beta-1 adrenergic activity which increases myocardial excitability and heart rate. While norepinephrine also stimulates beta-1 receptors, its primary effect is alpha-1 mediated vasoconstriction. The trial showed that this difference translates to a significantly higher rate of arrhythmias (24.1% vs 12.4%) in patients treated with dopamine.
Although the SOAP-II trial found no difference in the primary endpoint of 28-day mortality overall, which specific patient subgroup demonstrated a statistically significant mortality benefit when treated with norepinephrine?
Key Response
In the subgroup analysis of the 280 patients with cardiogenic shock, the use of dopamine was associated with a higher 28-day mortality compared to norepinephrine (p=0.03). This finding redirected clinical practice to favor norepinephrine as the foundational vasopressor even in cardiac-related shock states.
The SOAP-II trial utilized a double-blind design where the study drugs were prepared in identical infusions of 10mg/mL for dopamine and 0.8mg/mL for norepinephrine. How does this standardized titration approach influence our interpretation of 'dose-equivalent' hemodynamic support in clinical practice?
Key Response
The trial used a 1:12.5 concentration ratio based on the assumption that these doses provide roughly equivalent hemodynamic effects. By standardizing the titration, the researchers ensured that clinical outcomes were a result of the pharmacological properties of the molecules rather than clinician bias in dosing intensity, providing a robust comparison of efficacy and safety.
In light of the SOAP-II results, how should we teach the prioritization of 'safety endpoints' versus 'efficacy endpoints' when two therapeutic agents demonstrate no difference in primary mortality outcomes?
Key Response
SOAP-II is a landmark example of how safety signals (arrhythmias) can define the standard of care when efficacy (mortality) is equivalent. Teaching should emphasize that avoiding predictable iatrogenic complications is the deciding factor in choosing a first-line agent, effectively moving dopamine to a niche role for very specific cases like symptomatic bradycardia.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The SOAP-II trial reported a p-value of 0.03 for the cardiogenic shock subgroup analysis. Considering the trial was not stratified by shock type at the time of randomization, what statistical caveats must be considered when applying this finding to research design in future critical care trials?
Key Response
Unstratified subgroup analyses are susceptible to Type I errors and imbalances in baseline characteristics. A PhD researcher would note that while the interaction p-value suggests a potential effect, the study was not powered for this specific comparison, necessitating dedicated follow-up trials (like the subsequent IABP-SHOCK II or similar) to validate these post-hoc findings.
If the primary mortality endpoint was non-significant, what specific elements of the trial’s internal validity and design would a reviewer prioritize to justify its acceptance as a 'practice-changing' publication?
Key Response
A reviewer would look for the multicenter design, high adherence to the double-blind protocol, and the clinical relevance of the secondary safety endpoints. The fact that the trial addressed a fundamental, long-standing clinical uncertainty with a large sample size (1679 patients) provides sufficient editorial significance despite a negative primary result.
How do the SOAP-II findings specifically reconcile with current Surviving Sepsis Campaign (SSC) recommendations regarding the use of dopamine in septic shock?
Key Response
Current SSC guidelines recommend norepinephrine as the first-line vasopressor (Strong Recommendation, Moderate Quality of Evidence) and suggest using dopamine only in highly selected patients with low risk of tachyarrhythmias and absolute or relative bradycardia. This shift was directly informed by SOAP-II's evidence of increased arrhythmic risk and the lack of mortality benefit for dopamine.
Clinical Landscape
Noteworthy Related Trials
CAT Trial
Tested
Norepinephrine
Population
Patients with septic shock
Comparator
Epinephrine
Endpoint
28-day mortality
SEPSISPAM Trial
Tested
High mean arterial pressure target (80-85 mmHg)
Population
Patients with septic shock
Comparator
Low mean arterial pressure target (65-70 mmHg)
Endpoint
28-day mortality
VANISH Trial
Tested
Early vasopressin
Population
Patients with septic shock
Comparator
Norepinephrine
Endpoint
Kidney failure-free days
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis